FDA Approves First Targeted Therapy for NSCLC With KRAS Mutations
Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.